Winston-Salem, NC -- (SBWIRE) -- 11/01/2013 -- Nutranomics (OTCBB: NNRX) Trading at $0.46, Up $0.09. Today announced that it has entered into a non-binding Letter of Intent with Genesar Nutraceuticals, LLC ("Genesar"), with the intent of completing a licencing agreement to market and distribute GenEpic, a Genesar developed product that is currently undergoing FDA approved human clinical studies.
"GenEpic is an exciting and very promising natural treatment for prostate cancer that does not consist of chemotherapy or radiation, but rather focuses on adenosine-triphosphate (ATP) inhibition in cells," explained Nutranomics' CEO Dr. Tracy K. Gibbs. "For the past few weeks, we have been discussing the potential acquisition of the exclusive distribution rights to GenEpic and we are pleased that Genesar now wants to move forward to put together a formal licencing agreement. "GenEpic is a natural therapeutic formula containing 70 vitamins and minerals, 32 herbs, and 16 enzymes and phytonutrients, which are intended to help restore essential nutrients lost due to stress, aging, and disease.
GenEpic has been formulated by a respected team of five scientists and natural medicine experts, including Dr. Gibbs, to enhance bones/muscles, brain/memory, heart/circulatory function, mood, eyesight, metabolism, immune system, anti-oxidants, hormone support and digestive systems.
Case studies and previous clinical trials have shown that the GenEpic formula can have a positive effect in fighting disease. GenEpic is currently the subject of an FDA approved human clinical study on prostate cancer treatment and recovery that is expected to be completed within the next 30 days.
What They Do: Nutranomics is engaged in research and development of nutritional food products.
Copyright SmallCapReview. SmallCapReview.com has been a leading site for information on Small Cap Stocks, Penny Stocks and Microcaps since 1999. Visit http://SmallCapReview.com to sign up for our FREE newsletter.
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)